Hansa Biopharma AB launches new name and unveils logo

Lund, Sweden, February 1, 2019 – Hansa Biopharma AB, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today formally launched the Company’s new name. In December, the Company, formerly known as Hansa Medical AB, announced the name change had been approved by the ‘Bolagsverket’ in Sweden and that its stock ticker symbol had changed from “HMED” to “HNSA” on Nasdaq Stockholm.

Søren Tulstrup, CEO of Hansa Biopharma, comments: “Our new name, Hansa Biopharma, represents the next stage in the Company’s lifecycle and emphasizes our focus on the development and commercialization of biopharmaceuticals. The Hansa Biopharma logo expresses optimism and inspiration. Its dynamic form reflects the idea of a ‘hansa’ as a group of skilled individuals combining for a greater purpose, shining outward to represent the benefits we aim to deliver via our enzymology platform to people affected by a rare immunopathology.”

The corporate website, at the new address of www.hansabiopharma.com, will fully reflect the new identity over the coming weeks.

This change follows the approval, by the Bolagsverket in Sweden, of resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018.

The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CET on February 1, 2019.

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ)
Mobile: +46 707 175477
E-mail: emanuel.bjorne@hansabiopharma.com

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1 212 600 1902

About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm:HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.